The Science of Phosphatonin Metabolism: How Proteolytic Cleavage Controls Hormone Levels

Phosphatonins are hormones that help regulate phosphate balance in the body. The most studied of these is fibroblast growth factor 23 (FGF23). Understanding how FGF23 is cleared and degraded is key to grasping how phosphate levels stay in check—and how disorders arise when balance is lost.

FGF23: Role and Regulation

FGF23 is produced primarily by bone cells (osteocytes and osteoblasts). Its main actions are:

• Reducing phosphate reabsorption in the kidney
• Suppressing vitamin D activation (which otherwise raises blood phosphate)
• Modulating parathyroid hormone (PTH) secretion

By adjusting these pathways, FGF23 maintains serum phosphate in a healthy range (roughly 2.5–4.5 mg/dL in adults).

Key regulators of FGF23 production include:

• Serum phosphate levels
• Active vitamin D (1,25-dihydroxyvitamin D3)
• PTH
• Iron status and inflammation

When any of these signals change, bone cells alter FGF23 gene expression to restore balance.

Proteolytic Cleavage: The Molecular Brake

Even when FGF23 is secreted, its activity can be dialed down by proteolytic cleavage—cutting the intact hormone into inactive fragments. This process prevents excessive FGF23 signaling and helps fine-tune phosphate homeostasis.

The Cleavage Site

• FGF23 contains a specific sequence (arginine-179 to serine-180) recognized by proprotein convertases (furin and related enzymes).
• Cleavage at this site splits FGF23 into an N-terminal and C-terminal fragment, both biologically inactive.

Post-translational Modifications

Two key enzymes govern whether FGF23 is cleaved or remains intact:

1. GALNT3 (O-glycosyltransferase)

   • Adds an O-linked sugar to threonine 178, just next to the cleavage site.
   • This glycosylation blocks access by furin, favoring secretion of full-length (active) FGF23.

2. FAM20C (Kinase)

   • Phosphorylates serine 180, right at the cut point.
   • Phosphorylated serine promotes furin-mediated cleavage, increasing inactive fragments.

The balance between glycosylation and phosphorylation determines how much active FGF23 enters circulation.

FGF23 Clearance and Degradation Mechanisms

After secretion, intact FGF23 can be cleared in two main ways:

1. Proteolytic Degradation

   • Furin and related proprotein convertases in circulation and tissues cleave FGF23.
   • Liver and kidney cells may also participate in fragment uptake and breakdown.

2. Receptor-Mediated Endocytosis

   • Intact FGF23 binds to fibroblast growth factor receptors (FGFRs) in the presence of the co-receptor α-Klotho, especially in kidney tubules.
   • Bound hormone is internalized and degraded in lysosomes.

Factors influencing clearance:

• α-Klotho expression: Low levels limit receptor-mediated uptake, prolonging FGF23 action.
• Renal function: Reduced kidney filtration slows elimination of both intact hormone and fragments.
• Protease activity: Genetic or acquired changes in furin/GALNT3/FAM20C levels shift the balance of active vs. inactive FGF23.

Clinical Impact of Altered Cleavage

When the proteolytic control of FGF23 goes awry, phosphate disorders can follow:

• Excess FGF23 activity

  • Hypophosphatemia (low serum phosphate)
  • Rickets or osteomalacia (bone softening)
  • Common causes: X-linked hypophosphatemia, tumor-induced osteomalacia

• Reduced FGF23 activity

  • Hyperphosphatemia (high serum phosphate)
  • Ectopic calcifications (calcium deposits in soft tissues)
  • Seen in familial tumoral calcinosis (GALNT3 mutations)

Rare genetic mutations illustrate the importance of proteolytic cleavage:

• GALNT3 loss-of-function → decreased O-glycosylation → excessive cleavage → low intact FGF23 → hyperphosphatemia
• FAM20C deficiency → reduced phosphorylation → less cleavage → high intact FGF23 → hypophosphatemia

Therapeutic Approaches Targeting FGF23

Advances in understanding FGF23 metabolism have led to new treatments:

• Monoclonal antibodies against FGF23

  • Burosumab binds intact FGF23, preventing receptor interaction and alleviating hypophosphatemia in X-linked hypophosphatemia.

• Small molecules modulating proteases (under investigation)

  • Enhancing furin activity could increase FGF23 cleavage in cases of excessive hormone action.
  • Inhibiting GALNT3 or FAM20C may shift the active/inactive balance as needed.

• Dietary and phosphate binders

  • Reduce phosphate absorption, indirectly diminishing FGF23 production.

Monitoring and When to Seek Help

Symptoms of phosphate imbalance can be subtle (bone pain, muscle weakness) or serious (fractures, calcifications). If you experience concerning signs, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. If anything could be life-threatening or persistent, speak to a doctor promptly.

Key Takeaways

• FGF23 is a phosphatonin controlling phosphate via kidneys and vitamin D pathways.
• Proteolytic cleavage by furin and co-factors (GALNT3, FAM20C) regulates active hormone levels.
• Impaired clearance or degradation of FGF23 leads to phosphate disorders—either low or high serum phosphate.
• Targeted therapies aim to adjust FGF23 activity by interfering with cleavage or receptor binding.

Understanding the clearance and degradation mechanisms of FGF23 offers a roadmap for diagnosing and treating disorders of phosphate metabolism. Always discuss lab results and treatment options with your healthcare provider, especially if you have symptoms that could signal serious imbalance.